VivoSeq
Other

Survival

0

Pipeline Programs

5

Active Trials

3

Companies Involved

Survival is an early-stage landscape with 0 programs across 3 companies. The most active players are AstraZeneca, Quince Therapeutics S.p.A., Kun-Ming Rau.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

76/100

Attrition Rate

16/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

31

clinical trials

Completed16 · 52%
Unknown status5 · 16%
Terminated4 · 13%
Not yet recruiting2 · 6%
Recruiting2 · 6%
Withdrawn1 · 3%
Other1 · 3%

Trial Activity

31 trials

Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival
Not yet recruiting··N/A·NCT06512233·126 enrolled
Red Blood Cell (RBC) Survival Following Transfusion in Infants
Completed··Phase 2·NCT00731588·140 enrolled
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00242801·1,692 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)